Gradishar Stresses the Importance of Accurately Defining Breast Cancer Subtypes

Podcast

Dr Gradishar emphasizes the importance of defining metastatic breast cancer subtypes, the implications of molecular testing on treatment decisions, and the need for comprehensive patient-provider communication about therapeutic options and clinical trial opportunities throughout the course of disease.

Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we spoke with William J. Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology, chief of Hematology and Oncology, and a professor of hematology and oncology in the Department of Medicine at the Feinberg School of Medicine at Northwestern University.

In our exclusive interview, Dr Gradishar emphasized the importance of defining metastatic breast cancer subtypes and discussed the implications of molecular testing and genetics on treatment decisions. He also explained the process of determining disease subtypes as breast cancer cases shift from early-stage to metastatic, and highlighted the need for honest and comprehensive patient-provider communication about therapeutic options and clinical trial opportunities throughout the course of disease.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Carlos Arteaga, MD
Video 2 - "NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer"
Reshma L. Mahtani, DO
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "